Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1865348 | 0.88 | VCAM1 (0.56) | CA2CYP1A2MAPTLMNAHTT | |
| SCHEMBL2651409 | 0.88 | VCAM1 (0.56) | CA2CYP1A2MAPTLMNAHTT | |
| SCHEMBL9450021 | 0.86 | TSHR (0.55) | CA2TSHRMAPK1CYP1A2CA1 | |
| SCHEMBL1865824 | 0.86 | CASP6 (0.55) | CA2TSHRCYP1A2MAPTLMNA | |
| SCHEMBL2253267 | 0.85 | TSHR (0.53) | CA2TSHRMAPK1CYP1A2CA1 | |
| SCHEMBL2434953 | 0.83 | GAA (0.59) | CA2TSHRCYP1A2MAPTLMNA | |
| SCHEMBL7418264 | 0.83 | CYP1A2 (0.57) | CA2TSHRCYP1A2MAPTLMNA | |
| SCHEMBL6379699 | 0.83 | GAA (0.59) | CA2TSHRCYP1A2MAPTLMNA | |
| SCHEMBL10270605 | 0.82 | TSHR (0.58) | CA2TSHRMAPK1CYP1A2CA1 | |
| SCHEMBL3334862 | 0.82 | TSHR (0.62) | CA2TSHRMAPK1CYP1A2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590516-B1 | ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-07-11 | — | — | US | disclosed |
| CN-108349981-B | Novel pyrazolo [3, 4-d ] pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2021-03-30 | — | — | CN | disclosed |
| EP-3345907-B1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-25 | — | — | US | disclosed |
| CN-108349981-A | Novel pyrazolo [3, 4-d ] pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2018-07-31 | — | — | CN | disclosed |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. , LTD. (JP) | 2018-07-19 | — | — | US | disclosed |
| EP-3345907-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9920060-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-20 | — | — | US | disclosed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| CN-1349519-A | Glucokinase activators | HOFFMANN LA ROCHE (CH) | 2002-05-15 | — | — | CN | disclosed |
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | KESTER ROBERT F (US) | 2002-04-11 | — | — | US | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| WO-2002008209-A1 | ALPHA-ACYL AND ALPHA-HETEROATOM-SUBSTITUTED BENZENE ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | ZYX, DPYD, ZFX | CA2 1092/4885TSHR 2852/4885MAPK1 1493/4885 |
| US-20020042512-A1 | Alpha-acyl- and alpha-heteroatom-substituted benzene acetamide glucokinase activators | GCK, GCKR, ALDOA | CA2 196/4885TSHR 3506/4885MAPK1 2943/4885 |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | CA2 320/4885TSHR 857/4885MAPK1 39/4885 |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | CA2 1361/4885TSHR 3092/4885MAPK1 3703/4885 |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | ERBB2, JAK2, ERBB4 | CA2 320/4885TSHR 857/4885MAPK1 39/4885 |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | ZYX, DPYD, ZFX | CA2 1092/4885TSHR 2852/4885MAPK1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.